SRPT Quote, Financials, Valuation and Earnings

Biomarin Pharmaceutical has a net margin of 24.16% compared to Sarepta Therapeutics's net margin of 16.72%. Sarepta Therapeutics's return on equity of 20.83% beat Biomarin Pharmaceutical's return on equity of 8.09%.

Sarepta Therapeutics has a consensus price target of $179.46, signalling upside risk potential of 82.43%. On the other hand Biomarin Pharmaceutical has an analysts' consensus of $95.68 which suggests that it could grow by 37.78%. Given that Sarepta Therapeutics has higher upside potential than Biomarin Pharmaceutical, analysts believe Sarepta Therapeutics is more attractive than Biomarin Pharmaceutical.

Sarepta Therapeutics has a beta of 0.794, which suggesting that the stock is 20.639% less volatile than S&P 500. In comparison Biomarin Pharmaceutical has a beta of 0.330, suggesting its less volatile than the S&P 500 by 67.009%.

Sarepta Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biomarin Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sarepta Therapeutics pays -- of its earnings as a dividend. Biomarin Pharmaceutical pays out -- of its earnings as a dividend.

Sarepta Therapeutics quarterly revenues are $658.4M, which are smaller than Biomarin Pharmaceutical quarterly revenues of $747.3M. Sarepta Therapeutics's net income of $159M is higher than Biomarin Pharmaceutical's net income of $124.9M. Notably, Sarepta Therapeutics's price-to-earnings ratio is 43.14x while Biomarin Pharmaceutical's PE ratio is 31.56x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sarepta Therapeutics is 5.77x versus 4.83x for Biomarin Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

Madrigal Pharmaceuticals has a net margin of 24.16% compared to Sarepta Therapeutics's net margin of -57.51%. Sarepta Therapeutics's return on equity of 20.83% beat Madrigal Pharmaceuticals's return on equity of -63.91%.

Sarepta Therapeutics has a consensus price target of $179.46, signalling upside risk potential of 82.43%. On the other hand Madrigal Pharmaceuticals has an analysts' consensus of $401.67 which suggests that it could grow by 24.35%. Given that Sarepta Therapeutics has higher upside potential than Madrigal Pharmaceuticals, analysts believe Sarepta Therapeutics is more attractive than Madrigal Pharmaceuticals.

Sarepta Therapeutics has a beta of 0.794, which suggesting that the stock is 20.639% less volatile than S&P 500. In comparison Madrigal Pharmaceuticals has a beta of -0.403, suggesting its less volatile than the S&P 500 by 140.327%.

Sarepta Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Madrigal Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sarepta Therapeutics pays -- of its earnings as a dividend. Madrigal Pharmaceuticals pays out -- of its earnings as a dividend.

Sarepta Therapeutics quarterly revenues are $658.4M, which are larger than Madrigal Pharmaceuticals quarterly revenues of $103.3M. Sarepta Therapeutics's net income of $159M is higher than Madrigal Pharmaceuticals's net income of -$59.4M. Notably, Sarepta Therapeutics's price-to-earnings ratio is 43.14x while Madrigal Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sarepta Therapeutics is 5.77x versus -- for Madrigal Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 24.16% compared to Sarepta Therapeutics's net margin of -117.16%. Sarepta Therapeutics's return on equity of 20.83% beat Moderna's return on equity of -29.09%.

Sarepta Therapeutics has a consensus price target of $179.46, signalling upside risk potential of 82.43%. On the other hand Moderna has an analysts' consensus of $54.40 which suggests that it could grow by 58.59%. Given that Sarepta Therapeutics has higher upside potential than Moderna, analysts believe Sarepta Therapeutics is more attractive than Moderna.

Sarepta Therapeutics has a beta of 0.794, which suggesting that the stock is 20.639% less volatile than S&P 500. In comparison Moderna has a beta of 1.863, suggesting its more volatile than the S&P 500 by 86.269%.

Sarepta Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sarepta Therapeutics pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Sarepta Therapeutics quarterly revenues are $658.4M, which are smaller than Moderna quarterly revenues of $956M. Sarepta Therapeutics's net income of $159M is higher than Moderna's net income of -$1.1B. Notably, Sarepta Therapeutics's price-to-earnings ratio is 43.14x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sarepta Therapeutics is 5.77x versus 4.16x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of 24.16% compared to Sarepta Therapeutics's net margin of 31.35%. Sarepta Therapeutics's return on equity of 20.83% beat Vertex Pharmaceuticals's return on equity of -3.23%.

Sarepta Therapeutics has a consensus price target of $179.46, signalling upside risk potential of 82.43%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $496.70 which suggests that it could fall by -1.24%. Given that Sarepta Therapeutics has higher upside potential than Vertex Pharmaceuticals, analysts believe Sarepta Therapeutics is more attractive than Vertex Pharmaceuticals.

Sarepta Therapeutics has a beta of 0.794, which suggesting that the stock is 20.639% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.414, suggesting its less volatile than the S&P 500 by 58.629%.

Sarepta Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sarepta Therapeutics pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

Sarepta Therapeutics quarterly revenues are $658.4M, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.9B. Sarepta Therapeutics's net income of $159M is lower than Vertex Pharmaceuticals's net income of $913M. Notably, Sarepta Therapeutics's price-to-earnings ratio is 43.14x while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sarepta Therapeutics is 5.77x versus 11.84x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.